STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Clene Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Clene Inc. furnished an 8-K announcing third quarter 2025 financial results and recent operating highlights for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities. The filing also lists the company’s Nasdaq-listed common stock (CLNN) and warrants (CLNNW).

Positive
  • None.
Negative
  • None.
false 0001822791 0001822791 2025-11-13 2025-11-13 0001822791 clnn:CommonStock00001ParValueCustomMember 2025-11-13 2025-11-13 0001822791 clnn:WarrantsToAcquireOnefortiethOfOneShareOfCommonStockFor23000PerShareCustomMember 2025-11-13 2025-11-13


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2025

CLENE INC.
(Exact name of registrant as specified in its charter)

 
Delaware
001-39834
85-2828339
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of incorporation)
 
Identification No.)
     
6550 South Millrock Drive, Suite G50
Salt Lake City, Utah
 
84121
(Address of principal executive offices)
 
(Zip Code)
(801) 676-9695
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.0001 par value
 
CLNN
 
The Nasdaq Capital Market
Warrants, to acquire one-fortieth of one share of Common Stock for $230.00 per share
  CLNNW  
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 2.02 Results of Operations and Financial Condition.
 
On November 13, 2025, Clene Inc. (the “Company”) issued a press release announcing its third quarter 2025 financial results and recent operating highlights for its quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Number
 
by Exhibit Description
99.1
 
Press Release, dated November 13, 2025, announcing the Company’s third quarter 2025 financial results and recent operating highlights.
104
 
Cover Page Interactive Data File (formatted as Inline XBRL).
 
1

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
     
 
CLENE INC.
   
Date: November 13, 2025
By:
/s/ Robert Etherington
   
Robert Etherington
   
President and Chief Executive Officer
 
2
 

FAQ

What did CLNN announce in this 8-K?

The company furnished a press release announcing third quarter 2025 financial results and recent operating highlights.

Which period does Clene’s update cover?

It covers the quarter ended September 30, 2025.

What is Exhibit 99.1 in CLNN’s filing?

Exhibit 99.1 is a press release dated November 13, 2025 with the third quarter 2025 results and operating highlights.

Is the Item 2.02 information considered filed?

No. It is furnished, not filed, and is not subject to Section 18 of the Exchange Act.

What are Clene’s trading symbols and listings?

Common Stock trades as CLNN and Warrants as CLNNW on The Nasdaq Capital Market.

Who signed the report for CLNN?

It was signed by Robert Etherington, President and Chief Executive Officer.

What do CLNN’s listed warrants represent?

They are warrants to acquire one-fortieth of one share of Common Stock for $230.00 per share.
Clene

NASDAQ:CLNN

CLNN Rankings

CLNN Latest News

CLNN Latest SEC Filings

CLNN Stock Data

85.80M
7.23M
31.08%
16.55%
2.24%
Packaged Foods
Pharmaceutical Preparations
Link
United States
SALT LAKE CITY